Dr. Lubert Stryer Awarded 2006 National Medal of Science

Affymetrix Inc. (Nasdaq:AFFX) today announced that the Chairman of its Scientific Advisory Board, Lubert Stryer, M.D., was presented with the 2006 National Medal of Science from President George W. Bush at a White House ceremony on July 27, 2007. Dr. Stryer was awarded the nation’s highest honor for scientific achievement for his many contributions to molecular biology and biochemistry over the past four decades. "This is a well-deserved recognition for a man who has devoted himself to science and education,” said Stephen P.A. Fodor, Ph.D., founder, chairman and CEO of Affymetrix. "Lubert approaches science just as he approaches life, with imagination, dedication and a sense of urgency. We are honored to be a part of his life.” Dr. Stryer is the Mrs. George A. Winzer Professor of Cell Biology, Emeritus, and professor emeritus of neurobiology at Stanford University. He has made many landmark contributions in fluorescence energy transfer, light-directed chemical synthesis, and vision research and signal transduction. Of his most important contributions, one involved high-resolution light-directed chemical synthesis. Dr. Stryer, Dr. Fodor and colleagues developed this method and published the first description of microarray technology in a landmark Science publication in 1991. This same approach later became the underlying technology of Affymetrix. Dr. Stryer pioneered a number of fluorescence spectroscopy techniques and elucidated the molecular basis of amplification in vision. He also authored Biochemistry, a widely used textbook that is now in its sixth edition. "As an immigrant, I'm especially grateful to this country for having provided me with so many opportunities. I also greatly appreciate the wonderful interactions I have had with coworkers and colleagues in academic institutions and industry,” said Dr. Stryer. The National Medal of Science and Technology honors individuals for pioneering scientific research in a range of fields — including physical, biological, mathematical, social, behavioral and engineering sciences — that enhances our understanding of the world and leads to innovations and technologies that give the United States its global economic edge. Dr. Stryer is one of eight new laureates who were awarded medals. About Affymetrix Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,600 systems have been shipped around the world and more than 9,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com. Forward-looking Statements All statements in this press release that are not historical are "forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ "expectations,” "beliefs,” "hopes,” "intentions,” "strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties related to the implications of Dr. Lubert Stryer winning the 2006 National Medal of Science and Technology; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; uncertainties related to FDA and other regulatory approvals; competition; risks related to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.